Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Dean J KareemoDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0002-9575-0407
Christina S WinbornDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Samantha S OlahDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Carley N MillerDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0002-8746-7206
JungMin KimDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0002-1717-3675
Chelsie A KadgienDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0003-0238-6421
Hannah S Actor-EngelDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Harrison J RamsayDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0002-4536-9341
Austin M RamseyDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0002-5567-2619
Jason AotoDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.ORCID 0000-0003-0568-634X
Matthew J KennedyDepartment of Pharmacology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA. matthew.kennedy@cuanschutz.edu.ORCID 0000-0002-7029-7802
Funding
Novel approaches for interrogating and manipulating synaptic function, structure and plasticityR35NS116879 · NINDS · UNIVERSITY OF COLORADO DENVER · PI Matthew J Kennedy · 2020 to 2026
$4.0M
Functional and mechanistic interrogation of alpha neurexin extracellular domainsR01MH116901 · NIMH · UNIVERSITY OF COLORADO DENVER · PI AOTO, JASON · 2018 to 2022
$1.9M
Evaluating the functional impact of synaptic nanoarchitectureR01MH134957 · NIMH · UNIVERSITY OF COLORADO DENVER · PI Matthew J Kennedy · 2024 to 2026
$1.5M
Tools for manipulating protein condensates at the synapseR21MH134019 · NIMH · UNIVERSITY OF COLORADO DENVER · PI KENNEDY, MATTHEW J, TUCKER, CHANDRA L · 2023 to 2023
$429k
An optogenetic tool for acute modulation of inhibitory synaptic functionF32MH123053 · NIMH · UNIVERSITY OF COLORADO DENVER · PI OLAH, SAMANTHA · 2020 to 2023
$216k
Impact of stress on heroin seeking and ventral pallidal synapse functionF30DA057053 · NIDA · UNIVERSITY OF COLORADO DENVER · PI MILLER, CARLEY N · 2022 to 2024
$117k
Investigating the synaptic trafficking of endogenous AMPARsF31NS130979 · NINDS · UNIVERSITY OF COLORADO DENVER · PI KAREEMO, DEAN · 2023 to 2025
$93k
NIDA NIH HHS F30 DA057053NIMH NIH HHS F32 MH123053NIMH NIH HHS R01 MH116901NIMH NIH HHS R01 MH134957NIMH NIH HHS R21 MH134019NINDS NIH HHS F31 NS130979NINDS NIH HHS R35 NS116879U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) F32MH123053U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH134019U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) MH134957U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH116901U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) F31NS130979U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R35NS116879U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (NIDA) F30DA057053
6 · The paper itself
Abstract
Tools for visualizing and manipulating protein dynamics in living cells are critical for understanding cellular function. Here we leverage recently available monoclonal antibody sequences to generate a set of affinity tags for labeling and manipulating AMPA-type glutamate receptors (AMPARs), which mediate nearly all excitatory neurotransmission in the central nervous system. These antibodies can be produced from heterologous cells for exogenous labeling applications or directly expressed in living neurons as intrabodies, where they bind their epitopes in the endoplasmic reticulum and co-traffic to the cell surface for visualization with cell impermeant fluorescent dyes. We show these reagents do not perturb AMPAR trafficking, function, mobility, or synaptic recruitment during plasticity and therefore can be used as probes for monitoring endogenous receptors in living neurons. We also adapt these reagents to deplete AMPARs from the cell surface by trapping them in the endoplasmic reticulum, providing a simple approach for loss of excitatory neurotransmission. The strategies outlined here serve as a template for generating similar reagents targeting diverse proteins as more antibody sequences become available.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genetically encoded intrabody probes for labeling and manipulating AMPA-type glutamate receptors. · full record | OpenQuestion